JP2017518318A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017518318A5 JP2017518318A5 JP2016571256A JP2016571256A JP2017518318A5 JP 2017518318 A5 JP2017518318 A5 JP 2017518318A5 JP 2016571256 A JP2016571256 A JP 2016571256A JP 2016571256 A JP2016571256 A JP 2016571256A JP 2017518318 A5 JP2017518318 A5 JP 2017518318A5
- Authority
- JP
- Japan
- Prior art keywords
- fragment
- seq
- sequence
- antibody
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462008470P | 2014-06-05 | 2014-06-05 | |
| US62/008,470 | 2014-06-05 | ||
| PCT/US2015/034270 WO2015187992A2 (en) | 2014-06-05 | 2015-06-04 | Map44 polypeptides and constructs based on natural antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020171880A Division JP2021006581A (ja) | 2014-06-05 | 2020-10-12 | 天然抗体に基づくＭＡｐ４４ポリペプチドおよび構築物ならびにそれらの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017518318A JP2017518318A (ja) | 2017-07-06 |
| JP2017518318A5 true JP2017518318A5 (https=) | 2018-08-02 |
Family
ID=54767594
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016571256A Pending JP2017518318A (ja) | 2014-06-05 | 2015-06-04 | 天然抗体に基づくＭＡｐ４４ポリペプチドおよび構築物ならびにそれらの使用 |
| JP2020171880A Pending JP2021006581A (ja) | 2014-06-05 | 2020-10-12 | 天然抗体に基づくＭＡｐ４４ポリペプチドおよび構築物ならびにそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020171880A Pending JP2021006581A (ja) | 2014-06-05 | 2020-10-12 | 天然抗体に基づくＭＡｐ４４ポリペプチドおよび構築物ならびにそれらの使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20170209549A1 (https=) |
| EP (1) | EP3151845A4 (https=) |
| JP (2) | JP2017518318A (https=) |
| CN (1) | CN106687123A (https=) |
| AU (3) | AU2015269348C1 (https=) |
| CA (1) | CA2951159A1 (https=) |
| IL (1) | IL249368B (https=) |
| WO (1) | WO2015187992A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010034015A2 (en) | 2008-09-22 | 2010-03-25 | The Regents Of The University Of Colorado, A Body Corporate | Modulating the alternative complement pathway |
| WO2018075474A1 (en) * | 2016-10-17 | 2018-04-26 | Medical University Of South Carolina | Compositions and methods for treating central nervous system injury |
| EP3526249A4 (en) * | 2016-10-17 | 2020-07-01 | Musc Foundation for Research Development | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING INJURY ASSOCIATED WITH A GRAFT |
| EP3532034A4 (en) * | 2016-10-28 | 2020-12-02 | Washington University | ANTI-APOE ANTIBODY |
| TWI818919B (zh) * | 2017-08-15 | 2023-10-21 | 美商歐米諾斯公司 | 用於治療和／ 或預防與造血幹細胞移植有關的移植物抗宿主病和／ 或瀰漫性肺泡出血和／ 或靜脈閉塞性病的方法 |
| GB2583560A (en) | 2018-12-11 | 2020-11-04 | Admirx Inc | Fusion protein constructs for complement associated disease |
| MX2021006930A (es) * | 2018-12-11 | 2021-11-17 | Q32 Bio Inc | Construcciones de proteínas de fusión para enfermedades asociadas al complemento. |
| AU2021293174A1 (en) | 2020-06-14 | 2023-01-19 | Vertex Pharmaceuticals Incorporated | Complement Factor I-related compositions and methods |
| GB2628281A (en) * | 2022-01-07 | 2024-09-18 | Jumio Corp | Biometric authentication using head-mounted devices |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007112403A2 (en) * | 2006-03-27 | 2007-10-04 | The Regents Of The University Of Colorado | Prevention and treatment of ischemia-reperfusion injury |
| EP2520935A3 (en) * | 2006-08-09 | 2013-02-13 | Homestead Clinical Corporation | Organ-specific proteins and methods of their use |
| CN102781471B (zh) * | 2009-10-16 | 2016-10-12 | 奥默罗斯公司 | 通过抑制masp-2依赖性补体活化治疗弥散性血管内凝血的方法 |
| TW201241008A (en) * | 2010-10-01 | 2012-10-16 | Alexion Pharma Inc | Polypeptides that bind to human complement component C5 |
| US20120122107A1 (en) * | 2010-11-16 | 2012-05-17 | Aarhus Universitet | Homeostatic multidomain protein, and uses for it |
| KR102339315B1 (ko) * | 2012-06-18 | 2021-12-15 | 오메로스 코포레이션 | 다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법 |
| AU2014209350B8 (en) * | 2013-01-23 | 2019-04-18 | Department Of Veterans Affairs (Us) | Targeting constructs based on natural antibodies and uses thereof |
| WO2018075474A1 (en) * | 2016-10-17 | 2018-04-26 | Medical University Of South Carolina | Compositions and methods for treating central nervous system injury |
-
2015
- 2015-06-04 CN CN201580040628.7A patent/CN106687123A/zh active Pending
- 2015-06-04 US US15/316,113 patent/US20170209549A1/en not_active Abandoned
- 2015-06-04 EP EP15802708.6A patent/EP3151845A4/en not_active Withdrawn
- 2015-06-04 AU AU2015269348A patent/AU2015269348C1/en active Active
- 2015-06-04 JP JP2016571256A patent/JP2017518318A/ja active Pending
- 2015-06-04 CA CA2951159A patent/CA2951159A1/en active Pending
- 2015-06-04 WO PCT/US2015/034270 patent/WO2015187992A2/en not_active Ceased
-
2016
- 2016-12-04 IL IL249368A patent/IL249368B/en active IP Right Grant
-
2020
- 2020-10-12 JP JP2020171880A patent/JP2021006581A/ja active Pending
- 2020-12-07 US US17/113,612 patent/US20210213110A1/en not_active Abandoned
-
2021
- 2021-02-12 AU AU2021200908A patent/AU2021200908A1/en not_active Abandoned
-
2024
- 2024-03-25 US US18/614,952 patent/US20250000955A1/en active Pending
- 2024-06-24 AU AU2024204307A patent/AU2024204307A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017518318A5 (https=) | ||
| JP7587858B2 (ja) | ヒトｃｄ１３７に結合するアゴニスト性抗体およびその使用 | |
| AU2019201826B2 (en) | Targeting constructs based on natural antibodies and uses thereof | |
| JP7285813B2 (ja) | 多重特異性抗原結合分子およびその使用 | |
| CN112771077B (zh) | 针对cd3/cd20双特异性抗体的减轻细胞因子释放综合征的给药策略 | |
| ES2962260T3 (es) | Proteínas de fusión SIRPa alfa-anticuerpo | |
| JP6872537B2 (ja) | 抗ｌａｇ３抗体およびその使用 | |
| JP2023027258A (ja) | 改善された血清アルブミン結合性免疫グロブリン可変ドメイン | |
| JP2019535763A5 (https=) | ||
| US20230077885A1 (en) | Methods for dna-dependent targeting of a cell permeant antibody | |
| JP2020519643A5 (https=) | ||
| Li et al. | Generation of murine CTL by a hepatitis B virus-specific peptide and evaluation of the adjuvant effect of heat shock protein glycoprotein 96 and its terminal fragments | |
| JP7665600B2 (ja) | 抗腫瘍溶解性ウイルス抗原抗体およびその使用方法 | |
| US20190062428A1 (en) | Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof | |
| JP2017532952A5 (https=) | ||
| JP2016513080A5 (https=) | ||
| JP2017500018A5 (https=) | ||
| JP2012525128A5 (https=) | ||
| HRP20161656T4 (hr) | Sredstva za vezanje na cd33 | |
| EP3043819A1 (en) | Anti-vstm5 antibodies and the use thereof in therapy and diagnosis | |
| JP2018502060A5 (https=) | ||
| JP2019514361A5 (https=) | ||
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| JP2016524592A5 (https=) | ||
| JPWO2020059847A5 (https=) |